Human papillomavirus vaccine for children and adolescents;Le vaccin contre le virus du papillome humain pour les enfants et les adolescents

Paediatrics and Child Health

Volumn 12, Issue 7, 2007, Pages 599-610

  Bortolussi, Robert ^a   Moore, Dorothy L ^b   Robinson, Joan Louise ^c   Rousseau Harsany, Élisabeth ^d   Samson, Lindy Michelle ^e   MacDonald, Noni E ^a   Allen, Upton Dilworth ^f   Halperin, Scott Alan ^a   Hui, Charles P S ^e   Pickering, Larry ^g,h   Salvadori, Marina Ines ⁱ   Baltzer, Franziska ^c   Elliott, April ^j   Katzman, Debra ^f   Pinzon, Jorge ^k   Sankaran, Koravangattu ^l   Taddeo, Danielle ^d   Findlay, Sheri M ^m  

^a IWK HEALTH CENTRE   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c Sainte Justine UHC ^*

^d UNIVERSITY OF MONTREAL   (Canada)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g AMERICAN ACADEMY OF PEDIATRICS   (United States)

^h Children's Hospital of Western Ontario ^*  (United States)

ⁱ CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

^j ALBERTA CHILDREN'S HOSPITAL   (Canada)

^k BC CHILDREN S HOSPITAL   (Canada)

^l ROYAL UNIVERSITY HOSPITAL   (Canada)

^m MCMASTER CHILDREN S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

BRONCHOSPASM; CANADA; CANCER EPIDEMIOLOGY; CANCER PREVENTION; DIZZINESS; DRUG COST; DRUG HYPERSENSITIVITY; DRUG INDICATION; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPERTENSION; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MOTOR DYSFUNCTION; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SEXUAL TRANSMISSION; SYNCOPE; UTERINE CERVIX CANCER; VACCINATION; VAGINA BLEEDING; VERTICAL TRANSMISSION; VIRUS CARCINOGENESIS; VIRUS INFECTION; WART VIRUS;

EID: 35948932116     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/12.7.599     Document Type: Review

References (39)

1. Dobson S, Deeks S, Money D. National Advisory Committee on Immunization (NACI). Statement on human papillomavitus vaccine. An advisory committee statement (ACS). Can Commun Dis Rep 2007;33(ACS-2):1-31.
2. Money D, Roy M. Canadian consensus guidelines on human papillomavirus. 〈http://sogc.medical.org/home/pdf/hpv-guideline-full.pdf〉 (Version current at August 23, 2007).
3. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006;24(Suppl 3):S106-13.
4. Cason J, Mant CA. High-risk mucosal human papillomavirus infections during infancy & childhood. J Clin Virol 2005;32(Suppl 1):S52-8.
5. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26. (Erratum in 2003;157:858).
6. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl 3):S26-34.
7. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002;109:96-8.
8. Moscicki AB. Genital HPV infections in children and adolescents. Obstet Gynecol Clin North Am 1996;23:675-97.
9. Moore RA, Fornika DJ, Moravan V, et al. HPV type distribution in North America - a population-based study of 5000 British Columbia women. 23rd International Papillomavirus Conference & Clinical Workshop. Prague, September 1 to 7, 2006.
10. Healey SM, Aronson KJ, Mao Y, et al. Oncogenic human papillomavirus infection and cervical lesions in Aboriginal women of Nunavut, Canada. Sex Transm Dis 2001;28:694-700.
11. Young TK, McNicol P, Beauvais J. Factors associated with human papillomavirus infection detected by polymerase chain reaction among urban Canadian Aboriginal and non-Aboriginal women. Sex Transm Dis 1997;24:293-8.
12. Tunstall-Pedoe H. Preventing chronic diseases. A vital investment: WHO global report. Geneva: World Health Organization, 2005. Int J Epidemiol 2006.
13. Liu S, Semenciw R, Mao Y. Cervical cancer: The increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ 2001;164:1151-2.
14. Castellsagué X, Díaz M, de Sanjosé S, et al; ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15.
15. Canadian Cancer Society. Canadian Cancer Statistics 2006. 〈http://www.cancer.ca/vgn/images/portal/cit_86751114/31/21/ 935505792cw_2006stats_en.pdf.pdf〉 (Version current at August 23, 2007).
16. Boyce W, Doherty M, Fortin C, MacKinnon D. Canadian youth, sexual health and HIV/AIDS study: Factors influencing knowledge attitudes and behaviours. 〈http://www.cmec.ca/publications/aids/CYSHHAS_2002_EN.pdf〉 (Version current at August 23, 2007).
17. Boyce W. Young People in Canada: Their health and well-being. 〈http://www.phac-aspc.gc.ca/dca-dea/publications/hbsc-2004/pdf/ hbsc_report_2004_e.pdf〉 (Version current at August 23, 2007).
18. Canadian Association for Adolescent Health. Sexual behaviour and lack of knowledge threaten health of Canadian teens. 〈http://www.acsa-caah.ca/ang/ pdf/misc/research.pdf〉 (Version current at August 23, 2007).
19. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16 and 18. Vaccine 2006;24:5571-83.
20. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
21. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and Persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: A randomized controlled trial. Pediatr Infect Dis J 2007;26:201-9.
22. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45.
23. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66.
24. Garland SM, Hernandez-Avila M, Wheeler CM, et al; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
25. Merck Frosst Canada Limited. Product monograph: [Quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine] suspension for injection. Active immunizing agent. 〈http://www.hc-sc.gc.ca/dhp-mps/ alt_formats/hpfb-dgpsa/pdf/prodpharma/pm_mp_2006_gardasil_102682_partiii_e. pdf〉 (Version current at August 23, 2007).
26. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
27. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomized clinical trials. Lancet 2007;369:1693-702.
28. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-9.
29. Global Advisory Committee on vaccine safety. Wkly Epidemiol Rec 2007;82:252-9.
30. Middleman AB, Rosenthal SL, Rickert VI, Neinstein L, Fishbein DB, D'Angelo L; Society for Adolescent Medicine. Adolescent immunizations: A position paper of the Society for Adolescent Medicine. J Adolesc Health 2006;38:321-7.
31. Sanders G, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9:37-48.
32. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-9.
33. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-15.
34. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915-23.
35. Chesson HW. Cost effectiveness models of HPV vaccines. The 2006 National STD Prevention Conference. Jacksonville, May 9, 2006.
36. Dasbach EJ, Elbasha EH, Insinga RP. Immunization with a quadrivalent HPV vaccine: A cost-effectiveness analysis of alternative vaccination strategies in the United States. The 23rd International Papillomavirus Conference & Clinical Workshop. Prague, September 1 to 7, 2006.
37. Brisson M, Van de Velde N, De Wals P, Boily MC. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ 2007;177:464-8.
38. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007;25:5399-408.
39. MacDonald NE, Fisher WA, Wells GA, Doherty JA, Bowie WR. Canadian street youth: Correlates of sexual risk-taking activity. Pediatr Infect Dis J 1994;13:690-7.